A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care
Authors:
- Kritika Srinivasan RajsriKritika Srinivasan Rajsri
- Michael P. McRaeMMMichael P. McRae
- Glennon W. SimmonsGSGlennon W. Simmons
- Nicolaos J. ChristodoulidesNCNicolaos J. Christodoulides
- Hanover MatzHMHanover Matz
- Helen DooleyHDHelen Dooley
- Akiko KoideAKAkiko Koide
- Shohei KoideSKShohei Koide
- John T. McDevittJMJohn T. McDevitt
Open Access
- 10 August 2022
- journal article
- research article
- Published by MDPI AG in Biosensors
- Vol. 12 (8) , 621
Abstract
As of 8 August 2022, SARS-CoV-2, the causative agent of COVID-19, has infected over 585 million people and resulted in more than 6.42 million deaths worldwide. While approved SARS-CoV-2 spike (S) protein-based vaccines induce robust seroconversion in most individuals, dramatically reducing disease severity and the risk of hospitalization, poorer responses are observed in aged, immunocompromised individuals and patients with certain pre-existing health conditions. Further, it is difficult to predict the protection conferred through vaccination or previous infection against new viral variants of concern (VoC) as they emerge. In this context, a rapid quantitative point-of-care (POC) serological assay able to quantify circulating anti-SARS-CoV-2 antibodies would allow clinicians to make informed decisions on the timing of booster shots, permit researchers to measure the level of cross-reactive antibody against new VoC in a previously immunized and/or infected individual, and help assess appropriate convalescent plasma donors, among other applications. Utilizing a lab-on-a-chip ecosystem, we present proof of concept, optimization, and validation of a POC strategy to quantitate COVID-19 humoral protection. This platform covers the entire diagnostic timeline of the disease, seroconversion, and vaccination response spanning multiple doses of immunization in a single POC test. Our results demonstrate that this platform is rapid (~15 min) and quantitative for SARS-CoV-2-specific IgG detection.Keywords
Funding Information
- Renaissance Health Service Corporation
- Delta Dental of Michigan
- NIH (R42DA041959)
This publication has 64 references indexed in Scilit:
- Point‐of‐care oral cytology tool for the screening and assessment of potentially malignant oral lesionsCancer Cytopathology, 2020
- A microfluidic biochip platform for electrical quantification of proteinsLab on a Chip, 2018
- A paper/polymer hybrid microfluidic microplate for rapid quantitative detection of multiple disease biomarkersScientific Reports, 2016
- Programmable Bio-nanochip Platform: A Point-of-Care Biosensor System with the Capacity To LearnAccounts of Chemical Research, 2016
- Cardiac ScoreCard: A diagnostic multivariate index assay system for predicting a spectrum of cardiovascular diseaseExpert Systems with Applications, 2016
- Programmable bio-nano-chip system: a flexible point-of-care platform for bioscience and clinical measurementsLab on a Chip, 2015
- Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluidsDrug and Alcohol Dependence, 2015
- A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-CareCancer Prevention Research, 2015
- Laser-induced fluorescence integrated in a microfluidic immunosensor for quantification of human serum IgG antibodies to Helicobacter pyloriSensors and Actuators B: Chemical, 2012
- IgG anti-gliadin determination with an immunological microfluidic system applied to the automated diagnostic of the celiac diseaseAnalytical and Bioanalytical Chemistry, 2010